- Home
- ACXP
as 06-27-2025 4:00pm EST
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STATEN ISLAND |
| Market Cap: | 8.4M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 18.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $3.33 | Next Earning Date: | 08-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acurx Pharmaceuticals Inc. News
ACXP Breaking Stock News: Dive into ACXP Ticker-Specific Updates for Smart Investing
PR Newswire
10 days ago
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
Zacks
10 days ago
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
MT Newswires
11 days ago
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires
11 days ago
Top Midday Gainers
PR Newswire
11 days ago
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
ACCESS Newswire
19 days ago
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PR Newswire
19 days ago
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
PR Newswire
2 months ago
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
Compare ACXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACXP Acurx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.